September 26, 2022
Statement: Biogen Statement On Qui Tam Settlement

Biogen has reached a final agreement to pay $900 million to resolve previously disclosed qui tam litigation relating to speaker and consultant programs conducted by the Company prior to 2015. Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all

September 20, 2022

As part of its “Future of Work” initiative to optimize its office footprint in Cambridge to align with reduced space requirements under hybrid work models, today Biogen announced a sale and leaseback agreement with Boston Properties for its building at 125 Broadway and the termination of its lease

August 31, 2022
Statement on Alzheimer’s & Dementia® Journal Publication about Association between Reduction of Amyloid Beta and Slowing of Cognitive and Functional Decline in Alzheimer’s Disease

Today, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published an updated meta-analysis demonstrating a likely causal association between removal of amyloid beta plaques in the brain and slower cognitive and functional decline in Alzheimer’s disease.

June 15, 2022
Biogen Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner

On behalf of the Biogen community, we want to extend our deepest appreciation to Nancy Leaming and Brian Posner for their years of extraordinary service and dedication as members of our Board of Directors. Ms. Leaming and Mr. Posner, who joined the Biogen Board of Directors in 2008, will retire

April 29, 2022
Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US

The US Food and Drug Administration (FDA) has approved an updated full Prescribing Information for ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use, which includes further guidance on how to monitor patients and provides additional safety information.

April 28, 2022
Biogen To Offer Continuity of Care Plan for U.S. Patients Currently Treated with ADUHELM® (aducanumab-avwa)

Biogen is announcing plans to help patients in the U.S. currently on ADUHELM avoid any treatment interruptions following the final national coverage determination by Centers for Medicare & Medicaid Services (CMS) that could result in a loss of coverage for Medicare beneficiaries. All U.S.

April 22, 2022
Update on Regulatory Submission for Aducanumab in the European Union

Biogen Inc. (Nasdaq: BIIB) has notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for aducanumab for the treatment of the early stages of Alzheimer’s disease. The company withdrew its application following interactions with EMA’s

April 7, 2022
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease

This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class.

March 18, 2022
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper

The National Minority Quality Forum (NMQF) and Biogen will today discuss the importance of generating real-world evidence on a webinar hosted by NMQF on equitable access to research and care. Together, the organizations have also issued a white paper highlighting how real-world evidence (RWE) is

February 10, 2022
Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease

Biogen Response to CMS